MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ORGS - Orgenesis Inc
$6.75
0.39(6.13%)8:55:01 PM 1/25/2021
Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies. Orgenesis Inc. was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was founded in 2008 and is based in Germantown, Maryland.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    11/5/2020ORGS
    Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

    Reports rapid advancement of therapeutic pipeline Announces new semi-automated cell and gene therapy processing unitsReports cash and cash equivalents of $88.8 million as of September 30, 2020GERMANTOWN, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today provides a business update for the third quarter of 2020. Revenue increased 40% to $1.7 million co...

    11/3/2020ORGS
    Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders

    GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announced today that due to the public health impact of the COVID-19 pandemic and to support the health and well-being of its stockholders, the 2020 Annual Meeting, scheduled for November 18, 2020 at 10:00 am Eastern Time, will be held in a virtual format only. An in-person meeting will not be he...

    10/26/2020ORGS
    Did Orgenesis' (NASDAQ:ORGS) Share Price Deserve to Gain 44%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

    10/19/2020ORGS
    Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction

    Icellator® commercially available for lipotransfer in first two countries with more approvals expectedGERMANTOWN, Md., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced completion of the previously announced acquisition of Koligo Therapeutics, Inc. (“Koligo”), a regenerative medicine company. Additionally, the Company announced that it has acquir...

    09/29/2020ORGS
    Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

    Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitisGoal to rapidly advance KT-PC-301, an autologous cell therapy under investigation for the treatment of COVID-19-related Acute Respiratory Disease Syndrome (“ARDS”)Orgenesis to leverage Koligo’s 3D-V bioprinting technology across its POCare PlatformGERMANTOWN, Md., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ...

    09/9/2020ORGS
    Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th

    GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that CEO, Vered Caplan, will participate on a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10, 2020 at 1:00 p.m. ET.  The event brings together executives from leading biopharmaceutical companies to discuss ...

    08/20/2020ORGS
    Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

    GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), has entered into a Services Agreement with Therapeutics, Inc., a premier U.S. Clinical Research Organization (CRO) dedicated to dermatology product development. Under the agreement, the parties will collaborate for the development of Orgenesis’ Ranpirnase topical drug formulation for the t...

    08/7/2020ORGS
    Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

    Provides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020GERMANTOWN, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today provided a business update for the second quarter ended June 30, 2020. Vered Caplan, CEO of Orgenesis, stated, “We ...